India’s nutraceutical market is booming, with projections suggesting it will reach $18 billion by 2025, up from just $4 billion in 2020. As consumers increasingly turn to dietary supplements, functional foods, and health-enhancing products, the need for clear and effective regulatory oversight has never been more critical. However, navigating the regulations of nutraceuticals in India reveals a complex landscape marked by evolving guidelines, regulatory overlaps, and ongoing debates about the best path forward for consumer safety.
Table of Contents
Understanding the regulatory framework
The Food Safety and Standards Authority of India (FSSAI) serves as the primary regulatory body overseeing nutraceuticals in India. Operating under the Food Safety and Standards Act of 2006, FSSAI treats nutraceuticals as food products that offer health benefits beyond basic nutrition. The authority’s regulations cover eight distinct categories including health supplements, functional foods, foods for special dietary use, foods for special medical purposes, specialty foods containing botanicals, probiotics, prebiotics, and novel foods.
The Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food, and Novel Food) Regulations, 2016 established the foundational framework for nutraceutical regulation in India. These regulations specify permissible ingredients, set dosage limits based on recommendations from the Indian Council of Medical Research (ICMR), and outline labeling requirements to ensure consumers receive accurate product information.
The regulatory overlap challenge
One of the most significant challenges facing India’s nutraceutical sector involves the unclear boundary between food supplements and pharmaceutical products. Regulatory overlaps on dosage provisions between nutraceutical regulations and the Drugs and Cosmetics Act of 1940 have created confusion about whether certain products should be classified as nutraceuticals or drugs.
This ambiguity has led to practical problems in the marketplace. Some companies have shifted products from drug regulator oversight to food regulator oversight to take advantage of less stringent compliance requirements. Ingredients like melatonin and zinc carnosine, which were previously regulated as drugs, found their way into products approved by FSSAI, raising concerns about appropriate oversight levels for such substances.
Misleading claims and quality concerns
The absence of strict pre-market approval processes has allowed misleading health claims to flourish in the nutraceutical market. Many manufacturers make exaggerated or unsubstantiated claims about disease prevention, treatment, or cure-claims that would require rigorous clinical evidence if the products were regulated as pharmaceuticals. FSSAI’s FSS (Claims and Advertisements) Regulations, 2018 specify permissible nutritional and health claims, but enforcement remains challenging.
Quality control presents another significant challenge. Without mandatory medical supervision, consumers may take nutraceutical products for extended periods or in excessive doses, potentially causing harm. The simultaneous consumption of supplements and medications can lead to drug-nutrient interactions, while taking multiple supplements may result in nutrient antagonism-for instance, calcium from one supplement interfering with iron absorption from another.
Recent regulatory developments
Recognizing these challenges, the Indian government formed a high-level inter-ministerial committee in early 2024 to assess the regulatory framework for nutraceuticals. This committee, comprising representatives from the Ministry of Health, Ministry of Ayush, Department of Pharmaceuticals, FSSAI, and the Central Drugs Standard Control Organisation (CDSCO), examined whether certain nutraceutical products should be transferred from FSSAI’s oversight to CDSCO’s more stringent pharmaceutical regulatory framework.
The committee’s recommendations, released in November 2024, proposed clearer regulatory boundaries between simple vitamin and mineral supplements and more complex formulations. Simple supplements would remain under FSSAI’s jurisdiction, while high-potency products with specific dosages and pharmaceutical-grade excipients would potentially fall under CDSCO regulation. Products containing botanicals and plant extracts making disease risk reduction claims could be regulated by the Ministry of Ayush if they align with traditional medicine principles.
Interim measures and operational guidelines
While awaiting comprehensive regulatory reforms, FSSAI issued interim directions in August 2024 to re-operationalize certain provisions of the proposed 2022 regulations. This pragmatic approach allows businesses to continue operating under established guidelines while the inter-ministerial committee completes its review and new regulations are finalized.
The interim framework addresses immediate concerns about product safety and labeling while maintaining continuity in the marketplace. However, it also highlights the extended timeline required to develop comprehensive nutraceutical regulations that balance innovation, consumer protection, and industry growth.
Manufacturing and labeling requirements
Current regulations mandate that nutraceutical manufacturers obtain appropriate FSSAI licenses based on their business scale and operations. The licensing process requires detailed product information, safety assessments, manufacturing facility details, and compliance with Good Manufacturing Practices (GMP).
Labeling requirements ensure consumers receive essential information including product name, complete ingredient lists with allergen declarations, nutritional information, manufacturing and expiry dates, usage instructions, country of origin, and the FSSAI license number. The inter-ministerial committee has recommended separate GMP provisions specifically tailored for health supplements and nutraceuticals to ensure product quality and consistency.
Industry concerns about proposed changes
The nutraceutical industry has expressed significant concerns about the potential regulatory shift to CDSCO oversight. Industry experts argue that India’s current nutraceutical regulations align with international standards followed by food authorities in the United States, European Union, and Canada, where food regulators rather than drug authorities oversee dietary supplements.
Companies worry that stricter pharmaceutical-style regulations requiring clinical trials, extensive documentation, and longer approval timelines could stifle innovation and slow market growth during a critical expansion phase. The transition period alone could take five to six years, creating uncertainty that may harm business planning and investment decisions.
The path forward
India’s regulatory approach to nutraceuticals must balance multiple objectives: protecting consumer safety, ensuring product quality, preventing misleading claims, supporting industry innovation, and aligning with international standards. The current regulatory review process represents an opportunity to address longstanding challenges while creating a framework that can adapt to the sector’s rapid evolution.
Clear regulations governing manufacturing standards, labeling accuracy, permissible health claims, and ingredient safety will build consumer confidence and enable responsible industry growth. Whether oversight remains primarily with FSSAI, shifts partially to CDSCO, or develops into a hybrid model, the ultimate goal remains consistent: ensuring that Indians have access to safe, effective, and accurately labeled nutraceutical products that support their health and well-being.
As the inter-ministerial committee’s recommendations move toward implementation, stakeholders across the nutraceutical ecosystem-manufacturers, retailers, healthcare professionals, and consumers-will need to stay informed about regulatory changes and adapt their practices accordingly. The coming years will prove crucial in shaping India’s nutraceutical regulatory landscape for decades to come.
What do you think? How can India balance strict quality standards with the need to support innovation in the rapidly growing nutraceutical industry? What role should healthcare professionals play in guiding consumers toward safe and appropriate use of nutraceutical products?
References
- https://www.business-standard.com/health/govt-panel-set-to-review-if-nutraceuticals-should-be-brought-under-cdsco-124021800226_1.html
- https://fssai.gov.in/cms/health-supplements.php
- https://corporate.cyrilamarchandblogs.com/2024/12/cure-or-supplement-overlap-between-drugs-and-nutraceuticals/
- https://thehealthmaster.com/2024/11/13/recommendations-for-new-rules-for-nutraceuticals-fssai/
- https://www.lexology.com/library/detail.aspx?g=161c6999-8532-48aa-baee-b9d856bad19b
- https://www.artixio.com/post/nutraceutical-regulation-and-registration-in-india-fssai
- https://www.nutraingredients-asia.com/Article/2024/02/21/india-s-nutra-industry-could-die-why-experts-are-not-in-favour-of-drug-authority-regulating-nutraceuticals/
Leave a Reply